EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides

Xiaojie Wu, Jicheng Yu, Beikang Ge, Jeffrey Wang, Xiaoran Han, Chunye Zhang, Xiaomeng Mao, Hindu Kalluru, Candace Bramson, Steven G Terra, Jing Liu

Drugs in R&D · 2024

DOI: 10.1007/s40268-024-00467-5 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drugs in R&D, 2024. Verfasst von Xiaojie Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 3, Oligonucleotides, Antisense, Triglycerides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vupanorsen is a GalNAc3-conjugated antisense oligonucleotide targeting angiopoietin-like 3 (ANGPTL3) mRNA shown to reduce atherogenic lipoproteins in individuals with dyslipidemia. OBJECTIVES: The aim of this study was to satisfy Chinese regulatory requirements and support ethnic sensitivity assessment by evaluating pharmacokinetics (PK), pharmacodynamics (PD), and safety of vupanorsen in healthy Chinese adults with elevated triglycerides (TG). METHODS: In this phase I, parallel-cohort, open-label study, 18 Chinese adults with elevated fasting TG (≥ 90 mg/dL) were randomized 1:1 to receive a single subcutaneous dose of vupanorsen 80 mg or 160 mg. PK parameters, PD markers (including ANGPTL3, TG, non-high-density lipoprotein cholesterol [non-HDL-C]), and safety were assessed. RESULTS: Absorption of vupanorsen was rapid (median time to maximum concentration [Tmax]: 2.0 h for both doses), followed by a multiphasic decline (mean terminal half-life 475.9 [80 mg] and 465.2 h [160 mg]). Exposure (area under curve [AUC] and maximum plasma concentration [Cmax]) generally increased in a greater than dose-proportional manner from 80 mg to 160 mg. Time-dependent reductions in ANGPTL3 and lipid parameters were observed. Mean percentage change from baseline for the 80-mg and 160-mg doses, respectively, were - 59.7% and - 69.5% for ANGPTL3, - 41.9% and - 52.5% for TG, and - 23.2% and - 25.4% for non-HDL-C. No serious or severe adverse events (AEs), deaths, or discontinuations due to AEs were reported. Three participants experienced treatment-related AEs; all were mild and resolved by end of study. CONCLUSIONS: This study provided the first clinical vupanorsen data in China. In Chinese participants with elevated TG, PK and PD parameters were consistent with those reported previously in non-Chinese participants, including in Japanese individuals. No safety concerns were noted. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04916795.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiopoietin-Like Protein 3Oligonucleotides, AntisenseTriglyceridesAdultFemaleHumansMaleMiddle AgedYoung AdultAngiopoietin-like ProteinsChinaDose-Response Relationship, DrugHypertriglyceridemiaOligonucleotidesEast Asian People

Substanzen

Angiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanOligonucleotidesOligonucleotides, AntisenseTriglycerides

Autor:innen und Institutionen

  • Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Pfizer Pharmaceutical Ltd., Development China, 9/F, Tower B, Minmetals Plaza, No. 3-7 North Chaoyangmen Avenue, Dongcheng District, Beijing, China. Beikang.Ge@pfizer.com.
  • Pfizer Pharmaceutical Ltd., Development China, 9/F, Tower B, Minmetals Plaza, No. 3-7 North Chaoyangmen Avenue, Dongcheng District, Beijing, China.
  • Pfizer (China), Research and Development Co., Ltd., Shanghai, China.
  • Pfizer Healthcare India Private Limited, GPD Tamil Nadu, Chennai, India.
  • Pfizer Inc, Groton, CT, USA.

Förderung

  • Pfizer

Zitieren

APA

Wu, X., Yu, J., Ge, B., Wang, J., Han, X., Zhang, C., Mao, X., Kalluru, H., Bramson, C., Terra, S. G., & Liu, J. (2024). A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides. Drugs in R&D. https://doi.org/10.1007/s40268-024-00467-5

Vancouver

Wu X, Yu J, Ge B, Wang J, Han X, Zhang C, et al. A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides. Drugs in R&D. 2024. doi:10.1007/s40268-024-00467-5

BibTeX
@article{Wu2024,
  author = {Wu, Xiaojie and Yu, Jicheng and Ge, Beikang and Wang, Jeffrey and Han, Xiaoran and Zhang, Chunye and Mao, Xiaomeng and Kalluru, Hindu and Bramson, Candace and Terra, Steven G and Liu, Jing},
  title = {A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides},
  journal = {Drugs in R&D},
  year = {2024},
  doi = {10.1007/s40268-024-00467-5}
}
Kostenlos starten →